Tapinarof, a naturally occurring (now fully synthetic) AHR agonist, has shown promise in safely treating AD through phase 2 clinical trials, with phase 3 clinical trials underway (8, 13, 14). This evidence concerns the gene AHR and Alzheimer disease.